Clinical trials: Complication in Systemic Lupus Erythematosus
Nephritis, Systemic Lupus Erythematosus
Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, multiple dose escalation study, enrolling approximately 48 subjects.
- Trial name
- NCT00818948
- Testing
- AMG 811
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 56 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Background: Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. People with SLE are often treated with cyclophosphamide (CYC).
- Trial name
- NCT05567198
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Immunologic Diseases, Autoimmune Diseases
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.
- Conditions
- Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis
- Trial name
- NCT00035308
- Testing
- Abetimus sodium (LJP 394)
- Where
- 82 sites in United States, Austria and 8 more
- Volunteers
- 330 people
- Sponsor
- La Jolla Pharmaceutical Company
Lupus Nephritis
Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis
This study is composed of two stages: Part A is a randomized, double-blind, placebo-controlled dose-escalation study (i.e., Phase 1b study).
- Trial name
- NCT07044115
- Testing
- Recombinant Humanized Monoclonal Antibody MIL62 Injection
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Lupus Nephritis, Proteinuria
Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria
The purpose of this study is to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) and CTX in LN-V patients with gross proteinuria.
- Conditions
- Lupus Nephritis, Proteinuria, CTX
- Trial name
- NCT00935389
- Testing
- tripterygium glycosides
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Nanjing University School of Medicine
Periodontal Disease, Periodontitis
Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus…
- Conditions
- Periodontal Disease, Periodontitis, CKD, Chronic Kidney Disease
- Trial name
- PERIO-RA-RE (NCT07575347)
- Testing
- Observational assessment
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Stefan Lujinschi
Nephritis, Lupus
Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis
This a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment for the induction therapy of refractory lupus nephritis (LN).
- Trial name
- NCT01328834
- Testing
- Tacrolimus Sustained-release Capsules (ADVAGRAF)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Lupus Nephritis
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with…
- Trial name
- SYNERGY (NCT07225387)
- Testing
- Voclosporin
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- NephroNet, Inc.
Systemic Lupus Erythematosus, Lupus Nephritis
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis
Systemic lupus erythematosus (SLE) is an inflammatory, chronic, and multisystem autoimmune disease characterized by periods of activity and remission.
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Drug Monitoring, Mycophenolic Acid
- Trial name
- LUPUS-MONITOR (NCT07493655)
- Testing
- Therapeutic Drug Monitoring, Standard clinical care
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Federal University of Maranhao
Lupus Nephritis
Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)
Lupus nephritis (LN) is one of the most serious complications and the main cause of death in patients with systemic lupus erythematosus (SLE).The investigators have investigated the usefulness, and confirmed the efficacy and…
- Trial name
- NCT03580291
- Testing
- Mesenchymal stem cells, Mycophenolate Mofetil
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Lingyun Sun
Lupus Nephritis
BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB023 in participants with lupus nephritis (LN).
- Trial name
- NCT01930890
- Testing
- BIIB023, mycophenolate mofetil, oral corticosteroids
- Where
- 33 sites in United States, Argentina and 17 more
- Volunteers
- 87 people
- Sponsor
- Biogen
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis
To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.
- Trial name
- NCT02256150
- Testing
- Mizoribine (MZR), Cyclophosphamide (CTX)
- Where
- 26 sites in China
- Volunteers
- 250 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
study evaluates a biomarker-guided strategy to assign adults with refractory SLE to autologous CAR-T therapy targeting either CD19 or BCMA.
- Trial name
- SELECT-SLE (NCT07523542)
- Testing
- Autologous anti-CD19 CAR-T cells, intravenous single infusion at protocol-defined dose level (1 x 10^6 or 3 x 10^6 CAR-positive viable T cells/kg)., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Biotech
Lupus Nephritis
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
In this study, researchers will learn more about the use of felzartamab in people with active lupus nephritis, also known as LN. In people with LN, antibodies build up in the glomeruli of the kidneys.
- Trial name
- NCT06064929
- Testing
- Felzartamab
- Where
- 24 sites in United States, Argentina and 2 more
- Volunteers
- 14 people
- Sponsor
- HI-Bio, A Biogen Company
Healthy, Lupus Nephritis
Functional MRI in Lupus Nephritis
The primary objectives of the study are as follows: To develop and optimize a renal functional magnetic resonance imaging (MRI) protocol consisting of Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Blood-Oxygen…
- Trial name
- NCT01731054
- Where
- 4 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biogen
Lupus Nephritis, Children
Multicenter Registry of Pediatric Lupus Nephritis in China
This study is designed to evaluate the efficacy and safety of the current treatment option and outcome of pediatric lupus nephritis patients in China.
- Conditions
- Lupus Nephritis, Children, Steroid, Immunosuppressive Treatment
- Trial name
- NCT03791827
- Testing
- Corticosteroid, Hydroxychloroquine, Cyclophosphamide
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Xiqiang Dang
Lupus Nephritis
Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis
The goal of this prospective, multicenter,real-world study is to To evaluate the efficacy and safety of mescaline sodium enteric-coated tablets versus morte-mescaline in the treatment of adult patients with lupus nephritis under…
- Trial name
- NCT05933213
- Testing
- Mescaline sodium enteric-coated tablets, Morte-mescaline, Glucocorticoids
- Volunteers
- 205 people
- Sponsor
- Xiangya Hospital of Central South University
Systemic Lupus Erythematosus
Monoclonal Antibody Treatment for Systemic Lupus Erythematosus
This study will examine the safety and effects of the monoclonal antibody MRA in patients with systemic lupus erythematosus (SLE). Antibodies normally fight invading organisms.
- Trial name
- NCT00046774
- Testing
- MRA 003 US
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Lupus Nephritis
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
This was a pivotal, randomized, double-blind, placebo-controlled trial evaluating at Week 52 the efficacy and safety of secukinumab versus placebo in patients with active lupus nephritis (ISN/RPS Class III or IV, with or without…
- Trial name
- SELUNE (NCT04181762)
- Testing
- secukinumab
- Where
- 105 sites in United States, Argentina and 32 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
Prospective, multi-center, randomized, controlled, trial to compare tacrolimus with mycophenolate mofetil (MMF) for induces complete remission in lupus nephritis patients. The study duration is one year.
- Trial name
- NCT01580865
- Testing
- Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
- Where
- Thailand
- Volunteers
- 84 people
- Sponsor
- Ramathibodi Hospital